

Match Overview

1	Crossref 25 words Tomas Jelinek, Jana Mihalyova, Michal Kascak, Juraj Duras et al. "Single-agent venetoclax induces MRD-negative respo...	1%
2	Crossref 17 words Iuliana Vaxman, Hasib Siddiqi, Morie Gertz. "Venetoclax for treatment of multiple myeloma", Expert Review of Hematolog	1%
3	Internet 15 words crawled on 10-Nov-2019 aacr.org	1%
4	Crossref 14 words Wilson I. Gonsalves, Francis K. Buadi, Shaji K. Kumar. "Combination therapy incorporating Bcl-2 inhibition with Venetoclax...	1%
5	Crossref 12 words Hanley N. Abramson. "Kinase inhibitors as potential agents in the treatment of multiple myeloma", Oncotarget, 2016	<1%

Name of Journal: *World Journal of Clinical Cases*

Manuscript NO: 60323

Manuscript Type: CASE REPORT

Venetoclax in combination with chidamide and dexamethasone in relapsed/refractory primary plasma cell leukemia without t(11;14): A case report

Yang Y *et al.* Venetoclax and chidamide in primary plasma cell leukemia

Yang Yang, Li-Juan Fu, Chun-Mei Chen, Mei-Wei Hu



ALL

IMAGES

VIDEOS

12,000 Results

Any time ▾

[Venetoclax in Combination With Bortezomib, ...](#)

<https://www.clinical-lymphoma-myeloma-leukemia.com/...>

Jun 16, 2018 · Multiple myeloma (MM) is an incurable plasma cell (PC) dyscrasia with a 5-year overall survival of 50.7% that is estimated to currently affect 124,733 people in the United States.¹ Despite recent advances that have improved outcomes, MM inevitably becomes refractory to therapy, so clinicians must rely on a variety of treatment options for long-term disease management.

Cited by: 5

Author: Kian J. Rahbari, Jason D. Nosrati, Tanya ...

Publish Year: 2018

[Single-agent venetoclax induces MRD-negative response in ...](#)

<https://onlinelibrary.wiley.com/doi/10.1002/ajh.25331>

Oct 29, 2018 · To the Editor: Plasma cell leukemia (PCL) is the most aggressive form of plasma cell dyscrasia. It is characterized by the presence of more than 20% and/or more than 2×10^9 /L of circulating plasma cells (PCs). Primary plasma cell leukemia (pPCL) that presents de novo should be distinguished from secondary PCL, which corresponds to the leukemic transformation of pre-existing ...

Cited by: 7

Author: Tomas Jelinek, Jana Mihalyova, Michal K...

Publish Year: 2019

[Venetoclax or placebo in combination with bortezomib and ...](#)

[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045\(20\)30525-8/fulltext](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30525-8/fulltext)

The primary endpoint was met with a significant improvement in independent review committee-assessed progression-free survival with venetoclax versus placebo plus bortezomib and dexamethasone. However, increased mortality was seen in the venetoclax group, mostly because of an increased rate of infections, highlighting the importance of appropriate selection of patients for this ...

[The combination of venetoclax, daratumumab and ...](#)

<https://onlinelibrary.wiley.com/doi/full/10.1002/ajh.25676>

Nov 10, 2019 · In contrast, a relative low dose of venetoclax in combination with daratumumab and dexamethasone was highly effective and well tolerated in this elderly patient. Apart from his translocation t(11;14), the patient also harbored a bi-allelic inactivation of TP53, a very poor prognostic marker.

Cited by: 2

Author: Sos Nalghranyan, Amrit P. Singh, Carolin...

Publish Year: 2020

Venetoclax in combination with chidamide and dexamethasone in r



ALL

IMAGES

VIDEOS

9,250 Results

Any time ▾

[Venetoclax in Combination With Bortezomib, Dexamethasone ...](#)

<https://www.clinical-lymphoma-myeloma-leukemia.com/...>

Jun 16, 2018 · Multiple myeloma (MM) is an incurable **plasma cell** (PC) dyscrasia with a 5-year overall survival of 50.7% that is estimated to currently affect 124,733 people in the United States.¹ Despite recent advances that have improved outcomes, MM inevitably becomes **refractory** to therapy, so clinicians must rely on a variety of treatment options for long-term disease management.

Cited by: 5

Author: Kian J. Rahbari, Jason D. Nosrati, Tanya M....

Publish Year: 2018

[Single-agent venetoclax induces MRD-negative response in ...](#)

<https://onlinelibrary.wiley.com/doi/10.1002/ajh.25331>

Oct 29, 2018 · To the Editor: **Plasma cell leukemia** (PCL) is the most aggressive form of **plasma cell** dyscrasia. It is characterized by the presence of more than 20% and/or more than 2×10^9 /L of circulating **plasma cells** (PCs). **Primary plasma cell leukemia** (pPCL) that presents de novo should be distinguished from secondary PCL, which corresponds to the leukemic transformation of pre-existing ...

Cited by: 7

Author: Tomas Jelinek, Jana Mihalyova, Michal Ka...

Publish Year: 2019

[Venetoclax or placebo in combination with bortezomib and ...](#)

<https://www.thelancet.com/journals/lanonc/article/...>

The **primary** endpoint was met with a significant improvement in independent review committee-assessed progression-free survival with **venetoclax** versus placebo plus bortezomib and **dexamethasone**. However, increased mortality was seen in the **venetoclax** group, mostly because of an increased rate of infections, highlighting the importance of appropriate selection of patients for this treatment option.

Author: Shaji K Kumar, Simon J Harrison, Miche...

Publish Year: 2020

ALL

IMAGES

VIDEOS

MAPS

NEWS

SHOPPING

9,190 Results

Any time ▾

[Efficacy of venetoclax as targeted therapy for relapsed ...](#)

<https://ashpublications.org/blood/article/130/22/...> ▾

Nov 30, 2017 · **Venetoclax** is a selective, orally bioavailable BCL-2 inhibitor that induces **cell** death in multiple myeloma (MM) cells, particularly in those harboring **t(11;14)**, which express high levels of BCL-2 relative to BCL-X L and MCL-1. In this phase 1 study, patients with **relapsed/refractory** MM received **venetoclax** monotherapy.

Cited by: 206

Author: Shaji Kumar, Jonathan L. Kaufman, Cristina...

Publish Year: 2017

[A successful case of venetoclax-based therapy in relapsed ...](#)

<https://journals.sagepub.com/doi/10.1177/1078155219895072>

Dec 22, 2019 · Little data of **venetoclax**'s use has been published in **plasma cell leukemia**. We present a **case** of a **refractory/relapsed** sPCL patient displaying **t(11,14)** who achieved a very good partial response (VGPR) from **venetoclax** therapy in **combination** with **dexamethasone** and bortezomib.

Cited by: 1

Author: Allison Kupsh, Justin Arnall, Peter Voorhees

Publish Year: 2020

[Single-agent venetoclax induces MRD-negative response in ...](#)

<https://onlinelibrary.wiley.com/doi/10.1002/ajh.25331>

Oct 29, 2018 · To the Editor: **Plasma cell leukemia** (PCL) is the most aggressive form of **plasma cell** dyscrasia. It is characterized by the presence of more than 20% and/or more than 2×10^9 /L of circulating **plasma** cells (PCs). **Primary plasma cell leukemia** (pPCL) that presents de novo should be distinguished from secondary PCL, which corresponds to the leukemic transformation of pre-existing ...

Cited by: 7

Author: Tomas Jelinek, Jana Mihalyova, Michal Ka...

Publish Year: 2019

[Real-world data on safety and efficacy of venetoclax-based ...](#)

<https://onlinelibrary.wiley.com/doi/10.1111/bjh.16454>